中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(7): 1493-1497

Mechanism of action and potential therapeutic targets of ferroptosis suppressor protein 1 in liver diseases

DOI: 10.12449/JCH240731

  • Department of Endocrinology，Shanxi Provincial People’s Hospital，Shanxi Medical University，Taiyuan 030012，China

Research funding:

Natural Science Research General Project of Shanxi Province (202203021211059)

More Information
  • Corresponding author: QIN Jie， hopejieqin@sohu.com （ORCID： 0000-0002-7249-093X）
  • Received Date: 2023-12-02
  • Accepted Date: 2024-01-29
  • Published Date: 2024-07-25
    Abstract
  • Ferroptosis suppressor protein 1 （FSP1） is another major ferroptosis regulator besides glutathione peroxidase 4， which can scavenge intracellular reactive oxygen species and lipid peroxides and inhibit ferroptosis. In view of the key role of the liver in iron and lipid metabolism and its susceptibility to oxidative damage， more and more evidence has shown that FSP1 plays an important role in liver diseases such as metabolic associated fatty liver disease， hepatocellular carcinoma， acute liver failure， and alcoholic liver disease， and the related targets of FSP1 are expected to become a potential treatment option. This article comprehensively reviews FSP1， with a focus on the role of FSP1 in the pathophysiology of several common liver diseases and the potential of FSP1 as a target of liver diseases， in order to provide new ideas for the treatment of liver diseases.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149( 5): 1060- 1072. DOI: 10.1016/j.cell.2012.03.042.
    [2]
    YANG WS, SRIRAMARATNAM R, WELSCH ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156( 1-2): 317- 331. DOI: 10.1016/j.cell.2013.12.010.
    [3]
    BERSUKER K, HENDRICKS JM, LI ZP, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575( 7784): 688- 692. DOI: 10.1038/s41586-019-1705-2.
    [4]
    DOLL S, FREITAS FP, SHAH R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575( 7784): 693- 698. DOI: 10.1038/s41586-019-1707-0.
    [5]
    MAO C, LIU XG, ZHANG YL, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer[J]. Nature, 2021, 593( 7860): 586- 590. DOI: 10.1038/s41586-021-03539-7.
    [6]
    KRAFT VAN, BEZJIAN CT, PFEIFFER S, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J]. ACS Cent Sci, 2020, 6( 1): 41- 53. DOI: 10.1021/acscentsci.9b01063.
    [7]
    ZHENG JS, CONRAD M. The metabolic underpinnings of ferroptosis[J]. Cell Metab, 2020, 32( 6): 920- 937. DOI: 10.1016/j.cmet.2020.10.011.
    [8]
    KNIGHT TR, FARISS MW, FARHOOD A, et al. Role of lipid peroxidation as a mechanism of liver injury after acetaminophen overdose in mice[J]. Toxicol Sci, 2003, 76( 1): 229- 236. DOI: 10.1093/toxsci/kfg220.
    [9]
    OHIRO Y, GARKAVTSEV I, KOBAYASHI S, et al. A novel p53-inducible apoptogenic gene, PRG3, encodes a homologue of the apoptosis-inducing factor(AIF)[J]. FEBS Lett, 2002, 524( 1-3): 163- 171. DOI: 10.1016/s0014-5793(02)03049-1.
    [10]
    WU M, XU LG, LI XY, et al. AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis[J]. J Biol Chem, 2002, 277( 28): 25617- 25623. DOI: 10.1074/jbc.M202285200.
    [11]
    NOVO N, FERREIRA P, MEDINA M. The apoptosis-inducing factor family: Moonlighting proteins in the crosstalk between mitochondria and nuclei[J]. IUBMB Life, 2021, 73( 3): 568- 581. DOI: 10.1002/iub.2390.
    [12]
    MARSHALL KR, GONG M, WODKE L, et al. The human apoptosis-inducing protein AMID is an oxidoreductase with a modified flavin cofactor and DNA binding activity[J]. J Biol Chem, 2005, 280( 35): 30735- 30740. DOI: 10.1074/jbc.M414018200.
    [13]
    NGUYEN HP, YI D, LIN F, et al. Aifm2, a NADH oxidase, supports robust glycolysis and is required for cold- and diet-induced thermogenesis[J]. Mol Cell, 2020, 77( 3): 600- 617. DOI: 10.1016/j.molcel.2019.12.002.
    [14]
    ZENG FR, CHEN X, DENG GT. The anti-ferroptotic role of FSP1: Current molecular mechanism and therapeutic approach[J]. Mol Biomed, 2022, 3( 1): 37. DOI: 10.1186/s43556-022-00105-z.
    [15]
    MISHIMA E, ITO J, WU ZJ, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor[J]. Nature, 2022, 608( 7924): 778- 783. DOI: 10.1038/s41586-022-05022-3.
    [16]
    MLADĚNKA P, MACÁKOVÁ K, KUJOVSKÁ KRČMOVÁ L, et al. Vitamin K-sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity[J]. Nutr Rev, 2022, 80( 4): 677- 698. DOI: 10.1093/nutrit/nuab061.
    [17]
    YOSHIOKA H, KAWAMURA T, MUROI M, et al. Identification of a small molecule that enhances ferroptosis via inhibition of ferroptosis suppressor protein 1(FSP1)[J]. ACS Chem Biol, 2022, 17( 2): 483- 491. DOI: 10.1021/acschembio.2c00028.
    [18]
    YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): A systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/HEP.0000000000000004.
    [19]
    KOWDLEY KV, BELT P, WILSON LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012, 55( 1): 77- 85. DOI: 10.1002/hep.24706.
    [20]
    CRISMAN E, DUARTE P, DAUDEN E, et al. KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential[J]. Med Res Rev, 2023, 43( 1): 237- 287. DOI: 10.1002/med.21925.
    [21]
    SLOCUM SL, SKOKO JJ, WAKABAYASHI N, et al. Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet[J]. Arch Biochem Biophys, 2016, 591: 57- 65. DOI: 10.1016/j.abb.2015.11.040.
    [22]
    GAO G, XIE ZS, LI EW, et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis[J]. J Nat Med, 2021, 75( 3): 540- 552. DOI: 10.1007/s11418-021-01491-4.
    [23]
    VENKATESH D, O’BRIEN NA, ZANDKARIMI F, et al. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling[J]. Genes Dev, 2020, 34( 7-8): 526- 543. DOI: 10.1101/gad.334219.119.
    [24]
    KANE RC, FARRELL AT, MADABUSHI R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma[J]. Oncologist, 2009, 14( 1): 95- 100. DOI: 10.1634/theoncologist.2008-0185.
    [25]
    DOU T, ZHU XG, YANG H. Research progress on ferroptosis in hepatocellular carcinoma[J/CD]. Chin J Liver Dis Electron Version, 2023, 15( 4): 6- 10. DOI: 10.3969/j.issn.1674-7380.2023.04.002.

    窦婷, 朱向高, 杨昊. 铁死亡在肝细胞癌中的研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 4): 6- 10. DOI: 10.3969/j.issn.1674-7380.2023.04.002.
    [26]
    SUN XF, OU ZH, CHEN RC, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63( 1): 173- 184. DOI: 10.1002/hep.28251.
    [27]
    LIU MR, SHI C, SONG QY, et al. Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma[J]. Hepatol Commun, 2023, 7( 10): e0246. DOI: 10.1097/HC9.0000000000000246.
    [28]
    YUAN JS, LV T, YANG J, et al. HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma[J]. Redox Biol, 2022, 58: 102546. DOI: 10.1016/j.redox.2022.102546.
    [29]
    CHEU JW, LEE D, LI QD, et al. Ferroptosis suppressor protein 1 inhibition promotes tumor ferroptosis and anti-tumor immune responses in liver cancer[J]. Cell Mol Gastroenterol Hepatol, 2023, 16( 1): 133- 159. DOI: 10.1016/j.jcmgh.2023.03.001.
    [30]
    XAVIER DA SILVA TN, SCHULTE C, ALVES AN, et al. Molecular characterization of AIFM2/FSP1 inhibition by iFSP1-like molecules[J]. Cell Death Dis, 2023, 14( 4): 281. DOI: 10.1038/s41419-023-05787-z.
    [31]
    NAKAMURA T, HIPP C, SANTOS DIAS MOURÃO A, et al. Phase separation of FSP1 promotes ferroptosis[J]. Nature, 2023, 619( 7969): 371- 377. DOI: 10.1038/s41586-023-06255-6.
    [32]
    YANG J, JIA ZG, ZHANG J, et al. Metabolic intervention nanoparticles for triple-negative breast cancer therapy via overcoming FSP1-mediated ferroptosis resistance[J]. Adv Healthc Mater, 2022, 11( 13): e2102799. DOI: 10.1002/adhm.202102799.
    [33]
    HUANG S, WANG YH, XIE SW, et al. Hepatic TGFβr1 deficiency attenuates lipopolysaccharide/D-galactosamine-induced acute liver failure through inhibiting GSK3β-Nrf2-mediated hepatocyte apoptosis and ferroptosis[J]. Cell Mol Gastroenterol Hepatol, 2022, 13( 6): 1649- 1672. DOI: 10.1016/j.jcmgh.2022.02.009.
    [34]
    OYEWOLE AO, BIRCH-MACHIN MA. Mitochondria-targeted antioxidants[J]. FASEB J, 2015, 29( 12): 4766- 4771. DOI: 10.1096/fj.15-275404.
    [35]
    HE X, LIANG SM, WANG HQ, et al. Mitoquinone protects against acetaminophen-induced liver injury in an FSP1-dependent and GPX4-independent manner[J]. Toxicol Appl Pharmacol, 2023, 465: 116452. DOI: 10.1016/j.taap.2023.116452.
    [36]
    JAESCHKE H, RAMACHANDRAN A, CHAO XJ, et al. Emerging and established modes of cell death during acetaminophen-induced liver injury[J]. Arch Toxicol, 2019, 93( 12): 3491- 3502. DOI: 10.1007/s00204-019-02597-1.
    [37]
    LIU CY, WANG M, YU HM, et al. Ferroptosis is involved in alcohol-induced cell death invivo and invivo[J]. Biosci Biotechnol Biochem, 2020, 84( 8): 1621- 1628. DOI: 10.1080/09168451.2020.1763155.
    [38]
    LI Y, YANG S. Progress on alcoholic liver disease[J/CD]. Chin J Liver Dis Electron Version, 2022, 14( 3): 1- 4. DOI: 10.3969/j.issn.1674-7380.2022.03.001.

    李玥, 杨松. 酒精性肝病研究进展[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 3): 1- 4. DOI: 10.3969/j.issn.1674-7380.2022.03.001..
    [39]
    ZHANG Y, ZHAO S, FU Y, et al. Computational repositioning of dimethyl fumarate for treating alcoholic liver disease[J]. Cell Death Dis, 2020, 11( 8): 641. DOI: 10.1038/s41419-020-02890-3.
    [40]
    WARD NP, DENICOLA GM. Long-sought mediator of vitamin K recycling discovered[J]. Nature, 2022, 608( 7924): 673- 674. DOI: 10.1038/d41586-022-02001-6.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (599) PDF downloads(35) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return